WILMINGTON, DE — Incyte (Nasdaq: INCY) has entered a strategic collaboration with Edison Scientific to integrate an artificial intelligence platform across portions of its drug discovery and development operations, reflecting the pharmaceutical industry’s growing push to use AI to improve research productivity and accelerate decision-making.
The partnership will deploy Edison Scientific’s AI system, Kosmos, within Incyte’s research workflows, initially focusing on target discovery, target validation and translational biology.
Incyte plans to use the platform to analyze experimental, clinical and biomarker data, with the companies evaluating whether the technology improves research decisions and long-term pipeline productivity.
The collaboration represents a broader shift among drugmakers seeking to move beyond using artificial intelligence solely as a data-analysis tool and toward systems designed to continuously learn from research and clinical outcomes.
“Our vision is for our data to become a learning system that enhances every decision,” said Pablo J. Cagnoni, president and global head of research and development at Incyte.
Cagnoni said the company aims to use AI to improve experimental design and increase consistency in scientific and development decisions across its research programs.
The platform is expected to synthesize evidence from translational and clinical studies while generating predictive models intended to help researchers evaluate therapeutic performance.
Patrick Mayes, Incyte’s executive vice president and chief scientific officer, said learning from both experimental and clinical data could improve interpretation of results and strengthen future development efforts.
For Edison Scientific, the agreement provides an opportunity to embed its technology directly into a pharmaceutical company’s research infrastructure rather than deploying it as a standalone analytical tool.
“Every experiment, every clinical readout and every decision improves the underlying models,” said Edison Scientific Chief Executive Officer Sam Rodriques. “That is how companies, like Incyte, will turn their data into a sustainable advantage over their competitors.”
Financial terms of the collaboration were not disclosed.
The initial deployment will focus on selected research functions, though the companies indicated the technology could eventually expand across Incyte’s broader research and development organization.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.